Novalung and Medos start cooperation
future fund CEO Villinger, director Medos AG Dr. V. Hamm, Novalung management Dr. Matheis Bogenschütz and Strout (left to right)
The Zukunftsfonds Heilbronn (zfhn) announced that it has acquired Medos Medizintechnik AG from Ventizz Capital Partners Advisory AG. The purchase agreement was signed on January 7, 2011. With this acquisition medical device technology has become the most important sector for the private equity fund. Thomas Villinger, Managing Director of the zfhn, explained the decision behind this acquisition: ”The medical device sector is characterized by solid growth and is independent of economic cycles.“ He noted further that “Medos and Novalung are technological leaders is different markets, namely cardiac support and lung support. Their innovative technologies complement one another extremely well, and a close cooperation will enable even better utilization and speed up further developments.“
Dr. Volker Hamm, who has been named to join the Medos Management Board, noted with pleasure: “We are very happy about this development. Novalungs excellent market know-how in the field of lung support will provide a much broader customer base for our high-tech products.“ Hamm also noted that Christian Palme will join Thomas Villinger on the Supervisory Board of Medos. The Medos facilities in Stolberg und Radeberg will continue their operations after the acquisition.
Dr. Georg Matheis, Managing Director of Novalung GmbH since its founding eight years ago, emphasized that Novalung, after thousands of treatments using the company’s artificial lung, the iLA Membrane Ventilator®, has firmly established itself. “The innovative therapy for the treatment of lung failure without invasive mechanical ventilation is now well accepted” the former cardiothoracic surgeon noted. ”In order to further expand our market leadership as the pioneering company in this field, we will develop a full product portfolio in 2011. With the cooperation with Medos this can be accomplished more quickly than we originally expected.“ Matheis also pointed to the newest member of Novalung’s executive management team, Josef Bogenschütz, who left medical device company Maquet and join Novalung just a few weeks earlier. “In addition to strong leadership, Josef Bogenschütz brings with him great expertise in the development and manufacturing of artificial lungs. With him on board we are ideally positioned to aggressively develop additional innovative solutions for the replacement of invasive mechanical ventilation. Together, and with the support of our clinical partners, we will realize the vision of increasingly avoiding the damage of invasive mechanical ventilation.“
Bogenschütz, who most recently drove the successful growth of Maquet Cardiopulmonary AG as President and CEO, is equally optimistic concerning the expansion of the zfhn portfolio. ”I am pleased that this new cooperation provides so many areas of synergy for both companies. We will jointly leverage our know-how in the high-end cleanroom manufacturing of artificial lungs to further optimize our manufacturing efficiencies.“ He also presented Novalungs core strategy to intensify the company’s research and development activities and to further expand sales in the core markets in Europe and the USA.
Future Fund Heilbronn
Being a venture capital company, the Zukunftsfonds Heilbronn (future fund, short: ZFHN), founded in 2006, supports the development of young and technology based companies from the very first beginning when starting off with an innovative idea towards a successful enterprise. The focus is on promising sectors such as life science, IT, energy, industrial and environmental technology. The companies are accompanied by the ZFHN in a long run and established in the economic region of Heilbronn. Strengths of the Zukunftsfonds, in addition to its managers’ and directors’ high competence in economy, are the excellent connections to the regional and international economy.
Novalung‘s mission is to create new solutions for the treatment of lung failure with innovative artificial lungs that “breathe” outside the patient’s body. Instead of placing patients in an artificial coma so that they can tolerate mechanical ventilation, Novalung products enable the patients to rather experience their treatment while being awake, mobile and breathing easily.
Founded in 2003, the German company Novalung GmbH operates on a highly international level in order to establish new solutions for lung failure. These advanced technologies from Germany and the U.S. were brought into the company and developed further. From the outset Novalung has focused on high-quality development and production “Made in Germany“. Cutting-edge technologies are employed in Novalung’s medtech production facility in the manufacture in particular of the iLA Membrane Ventilator® and NovaPort® vascular access cannulas, both of which have been used to help treat thousands of patients.
Medos is a leading German medium-sized high-tech medical technology company that develops, manufactures and distributes medical devices for cardiac surgery and similar applications. The product portfolio consist of MEDOS tubing sets as basis and in-house developments as HILITE® oxygenators and reservoirs, the RHEOPARIN® coating (heparin), the DELTASTREAM® series, the MEDOS VAD system with divers ventricles and cannulas as well as a MEDOS cannula program.
Mrs Franziska Preissing
Head of Marketing
Tel.: +49 7131 27 06 130
Fax: +49 7131 27 06 230
Im Zukunftspark 1
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Novalung and Medos start cooperation here
News-ID: 159889 • Views: 6167
More Releases from Novalung GmbH
NovaPort twin, the Newest Double-Lumen Cannula, Approved
Novalung adds the unique double-lumen cannula to its expanding portfolio of products for the extrapulmonary treatment of lung failure. Now only a single cannula is required instead of two. Novalung announced today that it has received approval for the new NovaPort twin® double-lumen cannula, which is now available for clinical use. The NovaPort® twin cannula was specifically designed for veno-venous vascular access for the iLA activve® system - the Allrounder for
Novalung receives CE mark for iLA activve®
Novalung receives CE mark for iLA activve® With the new all-rounder for extrapulmonary lung support Novalung GmbH is the only company worldwide offering the complete portfolio for both pumpless and pump-driven lung support. Novalung announces receiving CE mark approval for their new pump-driven iLA activve® lung support system. It will be launched in Europe with immediate effect. Respiratory support with iLA activve® enables a treatment environment with awake, mobile patients instead
Josef Bogenschuetz joins Novalung as Managing Director
Novalung GmbH prepares for further growth with former Maquet CEO. As of January 1, 2011, Josef Bogenschütz and Dr. Georg Matheis are joint Managing Directors of Novalung GmbH. Bogenschütz will be specifically responsible for Research & Development, Manufacturing, Quality Management and Finance. This addition underscores the company’s focus on the ongoing and efficient expansion of its portfolio of innovative products designed to replace invasive mechanical ventilation. Nicholas L. Strout remains responsible
Novalung GmbH continues expansion into Scandinavia
The world’s first pumpless lung assist device, the iLA Membrane Ventilator®, now exclusively available in Sweden and Norway through Vingmed Group. Novalung GmbH, the German manufacturer of the world’s leading therapeutic system for extrapulmonary lung support, has signed exclusive agreements with Vingmed Svenska AB and Vingmed AS for distribution of the iLA Membrane Ventilator® in Sweden and Norway, respectively. Dr. Torsten Rinne, Medical Director of Novalung GmbH, noted: “We have seen
More Releases for Medos
Global Extracorporeal Membrane Oxygenation (ECMO) Systems Market Report 2019 Com …
#7th Edition Extracorporeal Membrane Oxygenation (ECMO) Systems market report recently has been published by market reports company. It features comprehensive market outlook based on historic data from 2013 to 2018 and estimated market trends during the forecast period from 2018 to 2026. To access complete insights of global Extracorporeal Membrane Oxygenation (ECMO) Systems market report: firstname.lastname@example.org The Extracorporeal Membrane Oxygenation (ECMO) Systems market delivers a wide array of primary and secondary
Membrane Oxygenator Market Significant Demand by 2021 | Top Companies are Medos …
Membrane Oxygenator Market Overview: A membrane oxygenator is a device used to add oxygen and remove carbon dioxide from the blood. It can be used in two ways, mimic the function of the lungs in cardiopulmonary bypass (CPB) and oxygenate the blood in the long term, called extracorporeal membrane oxygenation, ECMO. A membrane oxygenator consists of a thin gas-permeable membrane that separates the blood and gas flow in the CPB circuit;
Development Trends: Membrane Oxygenator Market By Key Vendors: Medos, Sorin, Kew …
Qyresearchreports include new market research report Membrane Oxygenator to its huge collection of research reports. This report studies the global Membrane Oxygenator market status and forecast, categorizes the global Membrane Oxygenator market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). A membrane
Membrane Oxygenator Market Forecast 2017-2022 Kewei Microport, WEGO, Medos, Sori …
Membrane Oxygenator Market Research 2017 A market study ” Global Membrane Oxygenator Market ” will help you understand, formulate and implement strategic decisions by offering critical data, insights and analysis from technology as well as commercial perspective on the Membrane Oxygenator market. It encloses an in-depth Research of the Membrane Oxygenator market state and the competitive landscape globally. This report consist of comprehensive market data, on a granular level, providing a
Medos Medizintechnik AG inaugurates new site
Management Board members Dr. Böhm and Mr. Bogenschütz officially inaugurated a new development site in Germany. The inauguration of the new Medos site is a further step forwards in the company's consistent implementation of its defined strategy of creating new technologies and therapeutic concepts. Medos develops, manufactures and markets products and therapies in the field of cardiac surgery for the treatment of heart attacks. The new development department in Reutlingen, Germany, will
Medos Medizintechnik AG gets a visual makeover
The changes that came with the company's newly-defined strategic focus are now clearly visible for the world to see. Medos presented its complete design makeover for the first time at the 25th Annual European Congress of Cardiac and Thoracic Surgeons (EACTS) in Lisbon in early October. The redesign is a logical consequence after the company’s repositioning. "We want Medos’ new, clear strategy to be reflected in our corporate design,"